Amneal Pharmaceuticals, Inc. (AMRX)
11.94
-0.12
(-1.00%)
USD |
NASDAQ |
Mar 27, 13:40
Amneal Pharmaceuticals Enterprise Value : 6.249B for March 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 210.95B |
| Apellis Pharmaceuticals, Inc. | 2.262B |
| ACADIA Pharmaceuticals, Inc. | 2.893B |
| BioMarin Pharmaceutical, Inc. | 9.766B |
| Corcept Therapeutics, Inc. | 3.733B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 49.57M |
| Revenue (Quarterly) | 814.32M |
| Total Expenses (Quarterly) | 779.24M |
| EPS Diluted (Quarterly) | 0.1069 |
| Gross Profit Margin (Quarterly) | 36.50% |
| Profit Margin (Quarterly) | 6.09% |
| Earnings Yield | 1.85% |
| Operating Earnings Yield | 10.29% |
| Normalized Earnings Yield | 2.601 |